Cargando…

Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study

BACKGROUND: Clinical trials have shown that erenumab is effective and well-tolerated for the preventive treatment of chronic migraine. To extend the results from clinical trials, we assessed the real-world efficacy and safety of erenumab in patients with chronic migraine from the outpatient clinic a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cullum, Christopher Kjaer, Do, Thien Phu, Ashina, Messoud, Bendtsen, Lars, Hugger, Sarah Sonja, Iljazi, Afrim, Gusatovic, Julia, Snellman, Josefin, Lopez-Lopez, Cristina, Ashina, Håkan, Amin, Faisal Mohammad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Milan 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164431/ https://www.ncbi.nlm.nih.gov/pubmed/35655137 http://dx.doi.org/10.1186/s10194-022-01433-9

Ejemplares similares

Interrelations between migraine-like headache and persistent post-traumatic headache attributed to mild traumatic brain injury: a prospective diary study
por: Ashina, Håkan, et al.
Publicado: (2020)

Calcitonin gene-related peptide causes migraine aura
por: Al-Khazali, Haidar M., et al.
Publicado: (2023)

Menstrual migraine is caused by estrogen withdrawal: revisiting the evidence
por: Raffaelli, Bianca, et al.
Publicado: (2023)

Second messenger signalling bypasses CGRP receptor blockade to provoke migraine attacks in humans
por: Do, Thien Phu, et al.
Publicado: (2023)

Premonitory symptoms in migraine: a systematic review and meta-analysis of observational studies reporting prevalence or relative frequency
por: Eigenbrodt, Anna K., et al.
Publicado: (2022)

Efficacy, tolerability, and safety of erenumab for the preventive treatment of persistent post-traumatic headache attributed to mild traumatic brain injury: an open-label study
por: Ashina, Håkan, et al.
Publicado: (2020)

Therapeutic novelties in migraine: new drugs, new hope?
por: Do, Thien Phu, et al.
Publicado: (2019)

Correction to: Therapeutic novelties in migraine: new drugs, new hope?
por: Do, Thien Phu, et al.
Publicado: (2019)

The Registry for Migraine (REFORM) study: methodology, demographics, and baseline clinical characteristics
por: Karlsson, William Kristian, et al.
Publicado: (2023)

Migraine induction with calcitonin gene-related peptide in patients from erenumab trials
por: Christensen, Casper Emil, et al.
Publicado: (2018)

Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension
por: Lipton, Richard B, et al.
Publicado: (2020)

Acute and preventive pharmacological treatment of post-traumatic headache: a systematic review
por: Larsen, Eigil Lindekilde, et al.
Publicado: (2019)

Psychiatric Sequelae Following Whiplash Injury: A Systematic Review
por: Al-Khazali, Haidar Muhsen, et al.
Publicado: (2022)

Timing and durability of response to erenumab in patients with chronic migraine
por: Tepper, Stewart J., et al.
Publicado: (2021)

Cluster headache – The worst possible pain on YouTube
por: Chaudhry, Basit Ali, et al.
Publicado: (2022)

Provoked versus spontaneous migraine attacks: pathophysiological similarities and differences
por: Ashina, Håkan, et al.
Publicado: (2022)

Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study
por: Diener, Hans-Christoph, et al.
Publicado: (2021)

Total tenderness score and pressure pain thresholds in persistent post-traumatic headache attributed to mild traumatic brain injury
por: Ashina, Håkan, et al.
Publicado: (2022)

Early onset of efficacy with erenumab in patients with episodic and chronic migraine
por: Schwedt, Todd, et al.
Publicado: (2018)

Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial
por: Tepper, Stewart J., et al.
Publicado: (2019)

Psychiatric and cognitive comorbidities of persistent post-traumatic headache attributed to mild traumatic brain injury
por: Ashina, Håkan, et al.
Publicado: (2021)

Assessment of Erenumab Safety and Efficacy in Patients With Migraine With and Without Aura: A Secondary Analysis of Randomized Clinical Trials
por: Ashina, Messoud, et al.
Publicado: (2021)

Plasma Levels of CGRP During a 2-h Infusion of VIP in Healthy Volunteers and Patients With Migraine: An Exploratory Study
por: Pellesi, Lanfranco, et al.
Publicado: (2022)

CGRP in migraine
por: Tfelt-Hansen, Peer, et al.
Publicado: (2009)

Targeting enkephalins and pituitary adenylate cyclase-activating polypeptide (PACAP) in migraine
por: Ashina, Messoud
Publicado: (2022)

One-quarter of individuals with weekly headache have never consulted a medical doctor: a Danish nationwide cross-sectional survey
por: Do, Thien Phu, et al.
Publicado: (2022)

Effect of Vasoactive Intestinal Polypeptide on Development of Migraine Headaches: A Randomized Clinical Trial
por: Pellesi, Lanfranco, et al.
Publicado: (2021)

Brain barriers and their potential role in migraine pathophysiology
por: Wiggers, Astrid, et al.
Publicado: (2022)

CGRP-induced migraine-like headache in persistent post-traumatic headache attributed to mild traumatic brain injury
por: Ashina, Håkan, et al.
Publicado: (2022)

Chronic headache and nitric oxide inhibitors
por: Ashina, Messoud, et al.
Publicado: (2001)

The changing faces of migraine
por: Martelletti, Paolo, et al.
Publicado: (2019)

Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials
por: Tepper, Stewart J, et al.
Publicado: (2021)

Shaping the future of migraine targeting Calcitonin-Gene-Related-Peptide with the Disease-Modifying Migraine Drugs (DMMDs)
por: Martelletti, Paolo, et al.
Publicado: (2019)

Calcitonin Gene-Related Peptide (CGRP) and Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) in Migraine Pathogenesis
por: Christensen, Casper Emil, et al.
Publicado: (2022)

Volume of the rectus capitis posterior minor muscle in migraine patients: a cross-sectional structural MRI study
por: Hvedstrup, Jeppe, et al.
Publicado: (2020)

Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine
por: Ashina, Messoud, et al.
Publicado: (2019)

Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial
por: Ashina, Messoud, et al.
Publicado: (2021)

Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation
por: Bendtsen, Lars, et al.
Publicado: (2018)

Long‐term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis
por: Ashina, Messoud, et al.
Publicado: (2022)

Imaging the inflammatory phenotype in migraine
por: Christensen, Rune Häckert, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ae75l4159djctroubba90n55m8